NRx Pharmaceuticals、Lotus Pharmaceuticals 與 Alvogen Inc. 宣布共同開發及商品化 NRX-101
June 06, 2023 19:14 ET
|
Lotus Pharmaceutical
NRx Pharmaceuticals、Lotus Pharmaceuticals 與 Alvogen 將共同進一步針對全球市場開發及商品化 NRX-101，用於治療具自殺傾向的難治型雙極性憂鬱 (S-TRBD)Lotus Pharmaceuticals 會取得 S-TRBD 治療藥物 NRX-101 的全球性權利，並且負責處理 NRX-101...
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
June 05, 2023 07:00 ET
|
Lotus Pharmaceutical
NRx Pharmaceuticals, Lotus Pharmaceuticals, and Alvogen to collaborate on the further development and commercialization of NRX-101 for suicidal treatment-resistant bipolar depression (S-TRBD) for...